Christophe Masseguin
Montpellier, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Time to collect informed consent to participate to randomized control trials in Intensive Care Unit patients: a single-center retrospective study over 7 years.
Journal: Minerva anestesiologica
Published: June 10, 2026
Evaluation of the performance and safety of adding the iron chelator MEX-CD1 to dialysate during continuous veno-venous haemodialysis for removing excess labile iron in intensive care patients with sepsis-associated acute kidney injury - the Iron in Intensive Care trial (IRON-I.C.): protocol for a phase I-II randomised crossover pilot study.
Journal: BMJ open
Published: December 23, 2025
Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.
Journal: Lancet (London, England)
Published: October 25, 2024
Pharmacometabolomics applied to low-dose interleukin-2 treatment in amyotrophic lateral sclerosis.
Journal: Annals of the New York Academy of Sciences
Published: May 21, 2024
Effect of Two Hydration Strategies on Capillary Sodium Concentrations in Runners Participating in 170-km Trail Race: The 2015 UltraTrail du Mont-Blanc Experience.
Journal: Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine
Published: March 24, 2024
Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2.
Journal: Brain communications
Published: January 05, 2021
Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial.
Journal: EBioMedicine
Published: March 31, 2020
French legal approach to clinical research.
Journal: Anaesthesia, critical care & pain medicine
Published: December 25, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026